Internal Oncology Pipeline

About SyntheX

SyntheX is a private, pre-clinical stage biotech leveraging synthetic biology to tackle the 'undruggable' proteome. Its core technology, the ToR FLEx platform, engineers cells to perform functional screens for compounds that modulate protein-protein interactions (PPIs) or induce targeted protein degradation (TPD), aiming to discover drugs with novel mechanisms of action. The company has built an internal pipeline in oncology, is actively seeking partnerships, and is led by a team with deep expertise in molecular biology, genetics, and drug development. SyntheX operates in a high-potential but competitive space, with its success hinging on platform validation and clinical translation.

Therapeutic Areas